Engineering lactococci and lactobacilli for human health

Current Opinion in Microbiology

Volumn 16, Issue 3, 2013, Pages 278-283

  Bermúdez Humarán, Luis G ^a   Aubry, Camille ^a   Motta, Jean Paul ^b,c,d   Deraison, Celine ^b,c,d   Steidler, Lothar ^e   Vergnolle, Nathalie ^b,c,d   Chatel, Jean Marc ^a   Langella, Philippe ^a  

^a UMR1319 MICALIS   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSERM   (France)

^d CNRS   (France)

^e ActoGeniX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ELAFIN; PROBIOTIC AGENT; PROTEINASE; SUPEROXIDE DISMUTASE;

ANTIINFLAMMATORY ACTIVITY; BIOENGINEERING; CELIAC DISEASE; COLITIS; CROHN DISEASE; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; GENETIC ENGINEERING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LACTOBACILLUS; LACTOBACILLUS CASEI; LACTOBACILLUS GASSERI; LACTOBACILLUS PLANTARUM; LACTOCOCCUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; ULCERATIVE COLITIS;

BOVINAE; LACTOCOCCUS; LACTOCOCCUS LACTIS; MURINAE; MUS;

EID: 84881542291     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.06.002     Document Type: Review

References (33)

1. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010, 7:503-514.
2. Seegers J.F. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002, 20:508-515.
3. Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., de Oca-Luna R.M., Langella P. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53:427-433.
4. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
5. Bermudez-Humaran L.G., Kharrat P., Chatel J.M., Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011, (10 Suppl. 1):S4.
6. Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can J Gastroenterol 2012, 26:909-915.
7. Levine J. Inflammatory bowel disease. Edited by J. B. Kirsner and R. G. Shorter. 832 pp. Baltimore, MD: Williams & Wilkins, 1995. Inflamm Bowel Dis 1995, 1:170-171.
8. Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007, 117:636-647.
9. Schmid M., Fellermann K., Fritz P., Wiedow O., Stange E.F., Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007, 81:907-915.
10. Sallenave J.M. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010, 42:635-643.
11. Shaw L., Wiedow O. Therapeutic potential of human elafin. Biochem Soc Trans 2011, 39:1450-1454.
12. Motta J.P., Magne L., Descamps D., Rolland C., Squarzoni-Dale C., Rousset P., Martin L., Cenac N., Balloy V., Huerre M., et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011, 140:1272-1282.
13. Motta J.P., Bermudez-Humaran L.G., Deraison C., Martin L., Rolland C., Rousset P., Boue J., Dietrich G., Chapman K., Kharrat P., et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012, 4:158ra144.
14. Weitzman S.A., Gordon L.I. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990, 76:655-663.
15. Gosselink M.P., Schouten W.R., van Lieshout L.M.C., Hop W.C.J., Laman J.D., Ruseler-van Embden G.H. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
16. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., Nicholls R.J., Gionchetti P., Campieri M., Kamm M.A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
17. Han W., Mercenier A., Ait-Belgnaoui A., Pavan S., Lamine F., van S., Kleerebezem M., Salvador-Cartier C., Hisbergues M., Bueno L. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis 2006, 12:1044-1052.
18. Rochat T., Bermudez-Humaran L., Gratadoux J.J., Fourage C., Hoebler C., Corthier G., Langella P. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb Cell Fact 2007, 6:22.
19. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., Klaenhammer T.R., Hassan H.M., Threadgill D.S. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G729-G738.
20. Watterlot L., Rochat T., Sokol H., Cherbuy C., Bouloufa I., Lefevre F., Gratadoux J.J., Honvo-Hueto E., Chilmonczyk S., Blugeon S., et al. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 2010, 144:35-41.
21. LeBlanc J.G., del Carmen S., Miyoshi A., Azevedo V., Sesma F., Langella P., Bermudez-Humaran L.G., Watterlot L., Perdigon G., de LeBlanc A.D. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011, 151:287-293.
22. Huibregtse I.L., Snoeck V., de Creus A., Braat H., De Jong E.C., Van Deventer S.J., Rottiers P. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007, 133:517-528.
23. Huibregtse I.L., Marietta E.V., Rashtak S., Koning F., Rottiers P., David C.S., van Deventer S.J., Murray J.A. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009, 183:2390-2396.
24. Takiishi T., Korf H., Van Belle T.L., Robert S., Grieco F.A., Caluwaerts S., Galleri L., Spagnuolo I., Steidler L., Van Huynegem K., et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012, 122:1717-1725.
25. Grillot-Courvalin C., Goussard S., Huetz F., Ojcius D.M., Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 1998, 16:862-866.
26. Guimaraes V.D., Innocentin S., Lefevre F., Azevedo V., Wal J.M., Langella P., Chatel J.M. Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol 2006, 72:7091-7097.
27. Chatel J.M., Pothelune L., Ah-Leung S., Corthier G., Wal J.M., Langella P. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther. 2008, 15:1184-1190.
28. Li Y.G., Tian F.L., Gao F.S., Tang X.S., Xia C. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus. Vaccine 2007, 25:902-911.
29. Innocentin S., Guimaraes V., Miyoshi A., Azevedo V., Langella P., Chatel J.M., Lefevre F. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol 2009, 75:4870-4878.
30. de Azevedo M., Karczewski J., Lefevre F., Azevedo V., Miyoshi A., Wells J.M., Langella P., Chatel J.M. In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin A. BMC Microbiol 2012, 12:299.
31. Zelmer A., Krusch S., Koschinski A., Rohde M., Repp H., Chakraborty T., Weiss S. Functional transfer of eukaryotic expression plasmids to mammalian cells by Listeria monocytogenes: a mechanistic approach. J Gene Med 2005, 7:1097-1112.
32. Steidler L., Neirynck S., Huyghebaert N., Snoeck V., Vermeire A., Goddeeris B., Cox E., Remon J.P., Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003, 21:785-789.
33. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., van Deventer S.J., Neirynck S., Peppelenbosch M.P., Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-759.